Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovate Biotechnology CoROCO:4130 -4.62%72 PEG Ratio is 131.62 as of Jul. 14, 2026, which is 689% above its 10-year median of 16.68. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 94 Biotechnology companies, Genovate Biotechnology Co ranks worse than 97.87% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Genovate Biotechnology Co's PEG Ratio or its related term are showing as below:
ROCO:4130'
s PEG Ratio Range Over the Past 10 Years
Min: 2.03 Med: 16.68 Max: 137.99
Current: 131.62
During the past 13 years, Genovate Biotechnology Co's highest PEG Ratio was 137.99. The lowest was 2.03. And the median was 16.68.
ROCO:4130's PEG Ratio is ranked worse than 97.87% of 94
companies
in the Biotechnology industry
Industry Median: 1.925
vs ROCO:4130: 131.62
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Genovate Biotechnology Co (ROCO:4130) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Genovate Biotechnology Co PEG Ratio Related Terms
Genovate Biotechnology Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4130 vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, Genovate Biotechnology Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovate Biotechnology Co PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Genovate Biotechnology Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Genovate Biotechnology Co (ROCO:4130) has a PEG Ratio of 131.62 as of Jul. 14, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genovate Biotechnology Co and its competitors. This is 689% above median its historical median of 16.68. Over the past decade, Genovate Biotechnology Co's PEG Ratio has ranged from 2.03 to 137.99. According to the industry distribution chart, Genovate Biotechnology Co ranks #92 out of 94 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Genovate Biotechnology Co's PEG Ratio too high?
Genovate Biotechnology Co's current PEG Ratio of 131.62 is 689% above median its 10-year median of 16.68. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 137.99. The Biotechnology industry median PEG Ratio is 1.93. Genovate Biotechnology Co's value of 131.62 is 6737.4% above this industry median. Based on the distribution chart, Genovate Biotechnology Co ranks #92 out of 94 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #92 out of 94 companies for PEG Ratio. This places Genovate Biotechnology Co in the lower half of its industry. The industry median PEG Ratio is 1.93. Genovate Biotechnology Co's value of 131.62 is 6737.4% above this benchmark. Historically, Genovate Biotechnology Co's own PEG Ratio has ranged from 2.03 to 137.99 over the past decade. While the company's 10-year median is 16.68 vs. the industry median of 1.93, Genovate Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.93, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovate Biotechnology Co's current PEG Ratio of 131.62 is 6737.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genovate Biotechnology Co and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovate Biotechnology Co's current PEG Ratio is 131.62, which is 689% above median its own 10-year median of 16.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current PEG Ratio is 131.62, which is 689% above median its 10-year median of 16.68 and 6737.4% above the Biotechnology industry median of 1.93. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current PEG Ratio is 131.62 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?
Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued.
The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20.
GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4130:
PEG Ratio: 131.62 (689% above median its 10-year median of 16.68)
GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
Industry Position: 6737.4% above the Biotechnology median (#92 of 94)
No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score
Get the complete analysis for ROCO:4130
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4130 has been successfully added to your 
